

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

UPDATE ANNOUNCEMENT IN RELATION TO THE AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the circular of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) dated 26 April 2023 (the “**Circular**”) and the announcements of the Company dated 3 May 2023, 9 May 2023 and 6 June 2023 (the “**Announcements**”) in relation to, among others, the proposed amendments to the articles of association of the Company. Unless otherwise defined, capitalised terms used in this announcement shall have the meanings as those defined in the Circular and the Announcements.

In light of the Consultation Conclusions on Rule Amendments Following Mainland China Regulation Updates and Other Proposed Rule Amendments Relating to PRC Issuers published by the Stock Exchange on 21 July 2023, the Proposed Amendments in respect of Articles 1 (save for the amendment of the third paragraph regarding the change of name of shareholders), 17 (save for the amendment of the third paragraph as a result of preceding amendment), 48, 61, 63, 67 (save for the additional paragraph thereunder), 79, 85, 86, 87, 88, 89, 90, 91, 92 and 100 will take effect from 1 August 2023.

By order of the Board

Zylox-Tonbridge Medical Technology Co., Ltd.

Dr. Jonathon Zhong Zhao

Chairman and Executive Director

Hong Kong, 26 July 2023

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.